Newsfile Corp
07 Oct 2026, 18:37 UTC · 4h ago
Impact · against what's priced in
Hemostemix gains a tangible catalyst through LARTA approval for its VesCell study and the avoidance of significant dilution from the cancelled CytoImmune deal. Ocugen's mention is nominal and unlikely to shift its current valuation.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish · 4 new · 0 priced in
Hemostemix received full approval from the LARTA Board for a commercial Phase 1 study of VesCell for angina, vascular dementia and pain.
Newannounces on October 7, 2026
More positive than 93% of claims this week
The company is raising up to $1,000,000 via a non-brokered private placement with units priced at C$0.05.
New
Continue reading
5 related stories
Full LARTA approval allows the company to begin its commercial Phase 1 study of VesCell for angina, vascular dementia, and pain, while the decision not to proceed with the CytoImmune license avoids the issuance of 20 million shares.
Read from the article alone
No priced-in read yet
The article merely references Ocugen's existing provisional LARTA approval for OCU400 to provide context for the regenerative-medicine community in The Bahamas.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
So whatThe initial closing of C$380,500 adds to the $682,250 raised since June 17, 2026.
More positive than 78% of claims this week
Hemostemix will not proceed with the CytoImmune bioreactor technology licence first announced on February 19, 2025.
Newannounced October 7, 2026
So whatThe company avoids issuing 20 million common shares, preventing the dilution that would have occurred if the deal closed.
More positive than 53% of claims this week
CytoImmune has completed ACP-01 test batches outside of the cleanroom and is moving production into the cleanroom.
Newannounced October 7, 2026
More positive than 53% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
Received full LARTA approval for its commercial Phase 1 study of VesCell and is raising additional capital.
More positive than 63% of ticker scores this week
Mentioned as having received provisional LARTA approval and priority designation for its gene therapy OCU400.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
1h ago
—
No price for HEM right now — the quote feed didn't answer.
HEM chart →−3.8%
Price is moving against the score
$1.00 vs $1.04 close before publication (Oct 6) · not market-adjusted
OCGN chart →
